Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Phase 3 data expected in the second half of 2024
he company posted total income during Q2 FY24 at Rs. 12.86 crore
The initiative will focus on advocating for cleaner air
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Subscribe To Our Newsletter & Stay Updated
